Biologic Therapies

  • Jeanne Tung
  • William J. Sandborn


Ulcerative Colitis Progressive Multifocal Leukoencephalopathy Crohn Disease Certolizumab Pegol Active Ulcerative Colitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Alimentary Pharmacology & Therapeutics 2005;21:251–8.CrossRefGoogle Scholar
  2. 2.
    Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflammatory Bowel Diseases 2006;12:22–8.PubMedCrossRefGoogle Scholar
  3. 3.
    den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29:2288–98.Google Scholar
  4. 4.
    van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the Rheumatic Diseases 2003;62:1168–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clinical Therapeutics 2003;25:1700–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology 2003;30:2563–2571.PubMedGoogle Scholar
  8. 8.
    van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the Rheumatic Diseases 2004;63:508–16.PubMedCrossRefGoogle Scholar
  9. 9.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis & Rheumatism 2004;50:1400–11.CrossRefGoogle Scholar
  10. 10.
    Rau R, Simianer S, van Riel PL, van de Putte LB, Kruger K, Schattenkirchner M, Allaart CF, Breedveld FC, Kempeni J, Beck K, Kupper H. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scandinavian Journal of Rheumatology 2004;33:145–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study G. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis & Rheumatism 2005;52:3279–89.CrossRefGoogle Scholar
  12. 12.
    van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, Jr., Group AS. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 2006;54:2136–46.CrossRefGoogle Scholar
  13. 13.
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn disease: the CLASSIC I trial. Gastroenterology 2006;130:323–333.PubMedCrossRefGoogle Scholar
  14. 14.
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn disease: results of the CLASSIC II trial. Gut 2007;56(9):1232–9.CrossRefGoogle Scholar
  15. 15.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn disease: the CHARM trial. Gastroenterology 2007;132:56–65.CrossRefGoogle Scholar
  16. 16.
    Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D’Haens G, Rosenfeld MR, Kent JD, Pollack P. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Annals of Internal Medicine 2007;146(12):829–38.Google Scholar
  17. 17.
    Panaccione R, Hanauer SB, Fedorak R, Rutgeerts P, Sandborn WJ, Pollack P. Concomitant immunosuppressive and adalimumab therapy in Crohn disease: 1-year results of the Classic II study. Gastroenterology 2006;130(Suppl 2):A-479.Google Scholar
  18. 18.
    Hanauer SB, D’Haens GR, Colombel JF, Sandborn WJ, Kent JD, Pollack PF. Sustained clinical remission in patients with moderate to severe Crohn disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy. American Journal of Gastroenterology 2006;101:S457 (Abstract 1173).Google Scholar
  19. 19.
    Schwartz D, Rutgeerts P, Colombel JF, Sandborn WJ, Hanauer SB, Kent JD, Pollack PF. Induction, maintenance, and sustainability of the healing of draining fistulas in patients with Crohn disease treated with adalimumab: results of the CHARM study. American Journal of Gastroenterology 2006;101:S458–459 (Abstract 1177).Google Scholar
  20. 20.
    Hanauer SB, Kamm MA, Colombel JF, Sandborn WJ, Rutgeerts P, Kent JD, Pollock PF. Sustained steroid-free clinical remission in patients with moderate to severe Crohn disease treated with adalimumab. American Journal of Gastroenterology 2006;101:S460 (Abstract 1181).CrossRefGoogle Scholar
  21. 21.
    Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn Disease. American Journal of Gastroenerology 2004;99:1984–1989.CrossRefGoogle Scholar
  22. 22.
    Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Loane J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn disease patients with an attenuated response to infliximab. American Journal of Gastroenerology 2005;100:75–79.CrossRefGoogle Scholar
  23. 23.
    Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. A pilot study of adalimumab in infliximab-allergic patients. Inflammatory Bowel Diseases 2004;10:333–338.PubMedCrossRefGoogle Scholar
  24. 24.
    Gassull MA, Hinojosa J, Garcia S, Bastida G, Saro C, Cabriada JL. Efficacy and safety of 4 weeks of adalimumab treatment in subjects with active luminal Crohn disease who lost response or showed intolerance to infliximab. Gastroenterology 2006;130(Suppl 2):W1197.Google Scholar
  25. 25.
    Gomollan F, Hinojosa J, Nos P, Penate M, Ceballos D, Gassull M. Four-week results of adalimumab treatment in subjects with fistulizing Crohn disease who have failed response or showed intolerance to infliximab. Gastroenterology 2006;130(Suppl 2):A-815.Google Scholar
  26. 26.
    Prescribing information for Humira (adalimumab). Package Insert 2004.Google Scholar
  27. 27.
    Deslandres C, Faure C, Dirks MH, Gervais F, Seidman EG. Open label experience with adalimumab in pediatric Crohn disease patients who lost response or were intolerant to infliximab. Gastroenterology 2006;130:A-656 Abstract W1199.Google Scholar
  28. 28.
    Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn disease. Journal of Pediatric Gastroenterology and Nutrition 2005;41:357–359.PubMedCrossRefGoogle Scholar
  29. 29.
    Lovell D, Ruperto N, Cuttica R, et al. Comparison of safety, efficacy and pharmacokinetics for 3 and 6mg/kg infliximab plus methotrexate therapy in JRA patients. Arthritis & Rheumatism 2005;52 (Suppl):S724.CrossRefGoogle Scholar
  30. 30.
    Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Adalimumab in the therapy of uveitis in childhood. The British Journal of Ophthalmology 2007;91:319–324.PubMedCrossRefGoogle Scholar
  31. 31.
    Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2006;54:890.CrossRefGoogle Scholar
  32. 32.
    Sanchez Munoz D, Hoyas Pablos E, Ramirez Martin Del Campo M, Nunez Hospital D, Guerrero Jimenez P. Gestacion a termino en paciente con enfermedad de Crohn en tratamiento con adalimumab. Gastroenterologia y Hepatologia 2005;28:435.PubMedCrossRefGoogle Scholar
  33. 33.
    Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn disease in pregnancy. Inflammatory Bowel Diseases 2006;12:827–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn disease of an ileoanal pouch during pregnancy. Digestive Diseases & Sciences 2006;51:2045–7.CrossRefGoogle Scholar
  35. 35.
    Prescribing information for Humira (adalimumab). 2007.Google Scholar
  36. 36.
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.PubMedCrossRefGoogle Scholar
  37. 37.
    Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006;65:889–94.PubMedCrossRefGoogle Scholar
  38. 38.
    Nesbitt AM, Henry AJ. High affinity and potency of the pegylated FAB’ fragment CDP870 – a direct comparison with other anti-TNF agents. American Journal of Gastroenerology 2004;99:S253.Google Scholar
  39. 39.
    Fossati G, Nesbitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). American Journal of Gastroenerology 2005;100(Supplement):S299.Google Scholar
  40. 40.
    Fossati G, Nesbitt A. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab PEGOL (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. American Journal of Gastroenerology 2005;100(Supplement):S298–S299.Google Scholar
  41. 41.
    Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A, for the CCsDSG. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn disease. Gastroenterology 2005;129:807–818.PubMedCrossRefGoogle Scholar
  42. 42.
    Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn disease: an exploratory study. Alimentary Pharmacology & Therapeutics 2004;20:1337–1346.CrossRefGoogle Scholar
  43. 43.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn disease. New England Journal of Medicine 2007;357:228–38.PubMedCrossRefGoogle Scholar
  44. 44.
    Schreiber S, Khaliq-Kareemi M, Lawrance I, Ostergond Thomsen O, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Certolizumab pegol maintenance therapy for Crohn disease. New England Journal of Medicine 2007;357:239–50PubMedCrossRefGoogle Scholar
  45. 45.
    Schreiber S, Feagan B, Hanauer SB, Rutgeerts P, McColm JA, Sandborn WJ. Safety and tolerability of subcutaneous (sc) certolizumab pegol in active Crohn disease (CD): results from two Phase III studies (PRECiSE program). Gastroenterology 2006;130:A-479 Abstract T1126.Google Scholar
  46. 46.
    Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 2002;41:1133–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn disease. Lancet 1997;349:521–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn disease: a randomised, double-blind, placebo-controlled trial. Gut 2004;53:1485–1493.PubMedCrossRefGoogle Scholar
  50. 50.
    Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, ArchambaultA, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn disease. Alimentary Pharmacology & Therapeutics 2005;21:373–384.CrossRefGoogle Scholar
  51. 51.
    Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP517, a humanized monoclonal antibody to tumor necrosis factor-a, for steroid-dependent Crohn disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology & Therapeutics 2006;23:617–628.CrossRefGoogle Scholar
  52. 52.
    Mamula P, Cohen SA, Ferry GD, Kirschner BS, Winter HS, Innes A, Patel J, Baldassano RN, Pediatric Inflammatory Bowel Disease C. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn disease. Inflammatory Bowel Diseases 2004;10:723–30.PubMedCrossRefGoogle Scholar
  53. 53.
    van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJH. Infliximab but not etanercept induces apopotosis in lamina propria T-lymphocytes from patients with Crohn disease. Gastroenterology 2003;124:1774–1785.PubMedCrossRefGoogle Scholar
  54. 54.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study G. Etanercept as monotherapy in patients with psoriasis.[see comment]. New England Journal of Medicine 2003;349:2014–22.PubMedCrossRefGoogle Scholar
  55. 55.
    Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Archives of Dermatology 2003;139:1627–32; discussion 1632.PubMedCrossRefGoogle Scholar
  56. 56.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study G. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British Journal of Dermatology 2005;152:1304–12.PubMedCrossRefGoogle Scholar
  57. 57.
    Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29–35.PubMedCrossRefGoogle Scholar
  58. 58.
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]. Lancet 2000;356:385–90.Google Scholar
  59. 59.
    Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis & Rheumatism 2004;50:2264–72.CrossRefGoogle Scholar
  60. 60.
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine 1999;130:478–86.PubMedGoogle Scholar
  61. 61.
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine 2000;343:1586–93.PubMedCrossRefGoogle Scholar
  62. 62.
    Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. The New England Journal of Medicine 2002;346:1349–56.PubMedCrossRefGoogle Scholar
  63. 63.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis & Rheumatism 2003;48:1667–75.CrossRefGoogle Scholar
  64. 64.
    Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study G. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis & Rheumatism 2003;48:3230–6.CrossRefGoogle Scholar
  65. 65.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Annals of the Rheumatic Diseases 2004;63:1594–600.PubMedCrossRefGoogle Scholar
  66. 66.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study I. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2006;65:1572–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. New England Journal of Medicine 2000;342:763–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for Active Crohn Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology 2001;121:1088–1094.PubMedCrossRefGoogle Scholar
  69. 69.
    Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Alimentary Pharmacology & Therapeutics 2003;17:185–92.CrossRefGoogle Scholar
  70. 70.
    Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Gild G, Schreiber S, Zignani M, Borghini-Fuhrer I, Pena Rossi C, the Onercept Study Group a. Onercept (recombinant human p55 tumor necrosis factor receptor) for moderate-to-severe Crohn disease: a randomized, double-blind, placebo-controlled trial. Clinical Gastroenterology & Hepatology 2006;4:888–893.CrossRefGoogle Scholar
  71. 71.
    Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW, International Natalizumab Multiple Sclerosis Trial G. A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2003;348:15–23.PubMedCrossRefGoogle Scholar
  72. 72.
    Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, Investigators A. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2006;354:899–910.PubMedCrossRefGoogle Scholar
  73. 73.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, Investigators S. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.New England Journal of Medicine 2006;354:911–23.PubMedCrossRefGoogle Scholar
  74. 74.
    Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn disease. Gastroenterology 2001;121:268–74.PubMedCrossRefGoogle Scholar
  75. 75.
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn disease. The New England Journal of Medicine 2003;348:24–32.PubMedCrossRefGoogle Scholar
  76. 76.
    Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn disease. New England Journal of Medicine 2005;353:1912–1925.PubMedCrossRefGoogle Scholar
  77. 77.
    Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, Panaccione R, Rutgeerts P, Schreiber S, Targan S, van Deventer S. Maintenance therapy with natalizumab does not require use of concomitant iImmunosuppressants for sustained efficacy in patients with active Crohn disease: results from the ENACT-2 study. Gastroenterology 2006;130:A-482 Abstract 1137.Google Scholar
  78. 78.
    Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, Rutgeerts P, Sandborn W, Schreiber S, Targan S, van Deventer S. Natalizumab maintains remission in patients with moderately to severely active Crohn disease for up to 2-years: results from an open-label extension study. Gastroenterology 2006;130:A-111 Abstract 768.Google Scholar
  79. 79.
    Targan S, Feagan B, Fedorak R, Lashner B, Panaccione R, Present D, Spehlmann M, Rutgeerts P, Zsolt T, Volfova M, Wolf D, Hernandez C, Bornstein J, Sandborn W. Natalizumab for the treatment of active Crohn disease: results of the ENCORE trial. Gastroenterology 2007;132(5):1672-83.CrossRefGoogle Scholar
  80. 80.
    Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn disease not in remission while receiving infliximab. Inflammatory Bowel Disease 2007;13:2–11.CrossRefGoogle Scholar
  81. 81.
    Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Alimentary Pharmacology & Therapeutics 2002;16:699–705.CrossRefGoogle Scholar
  82. 82.
    Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S, Group. INCT. Natalizumab therapy for moderate to severe Crohn disease in adolescents. Journal of Pediatric Gastroenterology and Nutrition 2007;44:185–191.PubMedCrossRefGoogle Scholar
  83. 83.
    Prescribing information for Tysabri (natalizumab). 2007.Google Scholar
  84. 84.
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. New England Journal of Medicine 2005;353:369–74.PubMedCrossRefGoogle Scholar
  85. 85.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. New England Journal of Medicine 2005;353:375–81.PubMedCrossRefGoogle Scholar
  86. 86.
    Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn disease. New England Journal of Medicine 2005;353:362–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Yousry TA, Major EO, Rysckewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephaolopathy. New England Journal of Medicine 2006;354:924–933.PubMedCrossRefGoogle Scholar
  88. 88.
    Feagan BG, Greenberg G, Wild G, McDonald JW, Fedorak R, Pare P, Kishimoto K, Gutierrez-Ramos JC, Krop J. Efficacy and safety of a humanized a4ss7 antibody in active Crohn disease (CD). Gastroenterology 2003;124:A25–A26.CrossRefGoogle Scholar
  89. 89.
    Feagan B, McDonald J, Greenberg G, Wild G, Pare P, Fedorak R, Landau S, LR B. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology 2000;118:A874.CrossRefGoogle Scholar
  90. 90.
    Feagan BG, Greenberg GR, Wild G, Fedorak R, Pare P, McDonald JWD, Dube R, Cohen A, Steinhardt H,Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. New England Journal of Medicine 2005;352:2499–2507.PubMedCrossRefGoogle Scholar
  91. 91.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR, Jr. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn disease. Gastroenterology 1998;114:1133–42.PubMedCrossRefGoogle Scholar
  92. 92.
    Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn disease. Gastroenterology 2001;120:1339–46.PubMedCrossRefGoogle Scholar
  93. 93.
    Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn disease. Gut 2002;51:30–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn disease. Alimentary Pharmacology & Therapeutics 2002;16:1761–70.CrossRefGoogle Scholar
  95. 95.
    Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn disease. Clinical Gastroenterology & Hepatology 2007;5:215–220.CrossRefGoogle Scholar
  96. 96.
    Maksymowych WP, Blackburn WD, Jr., Tami JA, Shanahan WR, Jr. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. Journal of Rheumatology 2002;29:447–53.PubMedGoogle Scholar
  97. 97.
    Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Alimentary Pharmacology & Therapeutics 2004;19:281–286.CrossRefGoogle Scholar
  98. 98.
    Miner PB, Jr., Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2006;23:1427–34.CrossRefGoogle Scholar
  99. 99.
    van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53:1646–1651.PubMedCrossRefGoogle Scholar
  100. 100.
    Van Deventer SJH, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Alimentary Pharmacology & Therapeutics 2006;23:1415–1425.CrossRefGoogle Scholar
  101. 101.
    Miner PB, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Alimentary Pharmacology & Therapeutics 2006;23:1403–1413.CrossRefGoogle Scholar
  102. 102.
    Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn disease: pathogenetic relevance and therapeutic implication. World Journal of Gastroenterology 2006;12:5606–10.PubMedGoogle Scholar
  103. 103.
    Neurath MF. IL-23: a master regulator in Crohn disease. Nature Medicine 2007;13:26–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461–3.PubMedCrossRefGoogle Scholar
  105. 105.
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Group A-I-CsDS. Anti-interleukin-12 antibody for active Crohn disease. New England Journal of Medicine 2004;351:2069–2079.PubMedCrossRefGoogle Scholar
  106. 106.
    Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ. Both IL-12p70 and IL-23 are synthesized during active Crohn disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflammatory Bowel Diseases 2006;12:9–15.PubMedCrossRefGoogle Scholar
  107. 107.
    Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. Journal of Investigative Dermatology 2004;123:1037–44.PubMedCrossRefGoogle Scholar
  108. 108.
    Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, Aria N, Gottlieb AB, Everitt DE, Frederick B, Pendley CE, Cooper KD. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. Journal of Immunology 2006;177:4917–26.Google Scholar
  109. 109.
    Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, Group CPS. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New England Journal of Medicine 2007;356:580–92.PubMedCrossRefGoogle Scholar
  110. 110.
    Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T, The Multiple Sclerosis I. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Current Medical Research & Opinion 2006;22:1671–8.CrossRefGoogle Scholar
  111. 111.
    Sandborn W, Feagan B, Fedorak R, Scherl E, Fleisher M, Katz S, Johanns J, Blank M, Rutgeerts P. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL-12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn disease. Gastroenterology 2007;132(Suppl 2):A51.Google Scholar
  112. 112.
    Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn disease. Inflammatory Bowel Disease 2006;12:558–565.CrossRefGoogle Scholar
  113. 113.
    Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. American Journal of Gastroenerology 2003;98:369–76.CrossRefGoogle Scholar
  114. 114.
    Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-ranging trial. Gut 2006;55:1568–1574.PubMedCrossRefGoogle Scholar
  115. 115.
    Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Alimentary Pharmacology & Therapeutics 2003;18:65–75.CrossRefGoogle Scholar
  116. 116.
    Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM, Basbuc I. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Alimentary Pharmacology & Therapeutics 2006;23:1435–42.CrossRefGoogle Scholar
  117. 117.
    Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. European Journal of Pediatrics 2002;161 Suppl 1:S88–92.PubMedGoogle Scholar
  118. 118.
    Hoover EG, DuBois JJ, Samples TL, McCullough JS, Chenaille PJ, Montes RG. Treatment of chronic enteritis in glycogen storage disease type IB with granulocyte colony-stimulating factor. Journal of Pediatric Gastroenterology & Nutrition 1996;22:346–50.CrossRefGoogle Scholar
  119. 119.
    Dieckgraefe BK, Korzenik JR. Treatment of active Crohn disease with recombinant human granulocyte- macrophage colony-stimulating factor. Lancet 2002;360:1478–80.PubMedCrossRefGoogle Scholar
  120. 120.
    Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn Disease Study G. Sargramostim for active Crohn disease. New England Journal of Medicine 2005;352:2193–201.PubMedCrossRefGoogle Scholar
  121. 121.
    Valentine JF, Fedorak RN, Fredlund P, Feagan BG. Sargramostim induces steroid-free remission in corticosteroid-dependent Crohn Disease: results of n.o.v.e.l. 2, a Phase II multicenter study. Gastroenterology 2007;132(Suppl 2):A502.Google Scholar
  122. 122.
    Feagan BG, Anderson F, Radford-Smith GL, Solovyov O, Zurdel-Dillinger S. Efficacy and safety of sargramostim in moderate to severe Crohn disease: Results of n.o.v.e.l. 4, a Phase III multicenter study. Gastroenterology 2007;132(Suppl 2):A103.Google Scholar
  123. 123.
    Mannon PJ, Leon F, Fuss IJ, et al. Increased IL-10 Production by Peripheral Blood Memory T Cells Accompanies Crohn Disease (CD) Remission and Clinical Response Induced by G-CSF Treatment. Gastroenterology 2006;130:W1220.Google Scholar
  124. 124.
    Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn disease. Alimentary Pharmacology & Therapeutics 2005;21:391–400.CrossRefGoogle Scholar
  125. 125.
    Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn disease. The New England Journal of Medicine 1999;340:239–40.PubMedCrossRefGoogle Scholar
  126. 126.
    Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003;38:859–68.PubMedGoogle Scholar
  127. 127.
    McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, Schlimgen R, Lee E, Foster B, Flemming D, Prussin C, Fleisher TA, Boumpas DT. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. Journal of Immunology 2001;167:4075–82.Google Scholar
  128. 128.
    Maini R, Paulus HE, Breedveld FC. rHuIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study. Arthritis & Rheumatism 1997;S224.Google Scholar
  129. 129.
    Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. Journal of Rheumatology 1999;26:2089–93.PubMedGoogle Scholar
  130. 130.
    van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn disease. Crohn Disease Study Group. Gastroenterology 1997;113:383–9.PubMedCrossRefGoogle Scholar
  131. 131.
    Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473–82.PubMedCrossRefGoogle Scholar
  132. 132.
    Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn disease. Crohn Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461–72.PubMedCrossRefGoogle Scholar
  133. 133.
    Fedorak R, Nielsen O, Williams N, Malchow H, Forbes A, Stein B, Wild G, Lashner B, Renner E, Buchman A, Hardi R, group ati-s. Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn disease. Gastroenterology 2001;120:A-127.CrossRefGoogle Scholar
  134. 134.
    Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, Koningsberger JC, Abreu L, Kuhn I, Cohard M, LeBeaut A, Grint P, Weiss G. Treatment of Crohn disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002;50:191–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn disease. Gut 2001;49:42–6.PubMedCrossRefGoogle Scholar
  136. 136.
    Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin- 10. Science 2000;289:1352–5.PubMedCrossRefGoogle Scholar
  137. 137.
    Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnology 2003;21:785–9.PubMedCrossRefGoogle Scholar
  138. 138.
    Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis. European Journal of Pharmaceutics & Biopharmaceutics 2005;59:9–15.CrossRefGoogle Scholar
  139. 139.
    Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. European Journal of Pharmaceutics & Biopharmaceutics 2005;60:349–59.CrossRefGoogle Scholar
  140. 140.
    Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn disease. Clinical Gastroenterology & Hepatology 2006;4:754–9.CrossRefGoogle Scholar
  141. 141.
    Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn disease. Gut 2006;55:1138–44.PubMedCrossRefGoogle Scholar
  142. 142.
    Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D’Haens G, Van Assche G, Ba S, Lee S, Pearce T. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn disease. Gut 2006;55:1131–7.PubMedCrossRefGoogle Scholar
  143. 143.
    Plevy S, Salzberg B, van Assche G, Regueiro M, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Lowder J. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Results of a phase I study. Gastroenterology 2004;126:A75.Google Scholar
  144. 144.
    Targan SR, Salzberg BA, Mayer L, Hommes D, Hanauer S, Mahadevan U, Reinisch W, Plevy SE, Dignass AU, Van Assche G, Buchman A, Mechkov G, Krastev Z, Lowder JN. A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids (IVSR-UC). Gastroenterology 2005;128(Suppl 4):A75.Google Scholar
  145. 145.
    Hommes DW, Targan SR, Dignass A, Baumgart DC, Mayer L, Zang L, Wilson K, Lowder J, Frankel M. Visilizumab therapy in subjects with moderate-to-severe, refractory Crohn disease. Gastroenterology 2007;132(Suppl 2):A157.Google Scholar
  146. 146.
    Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ, Group RDPIS. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflammatory Bowel Diseases 2005;11:713–9.PubMedCrossRefGoogle Scholar
  147. 147.
    Preliminary results of Sangstat’s phase 2 studies of RDP58 show peak response of 77% and a 71% remission rate in ulcerative colitis patients. Additional investigation needed to determine efficacy in Crohn disease. Internet Press Release 2003.Google Scholar
  148. 148.
    Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis & Rheumatism 2002;46:1470–9.CrossRefGoogle Scholar
  149. 149.
    Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New England Journal of Medicine 2003;349:1907–15.PubMedCrossRefGoogle Scholar
  150. 150.
    Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis & Rheumatism 2005;52:2263–71.CrossRefGoogle Scholar
  151. 151.
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.. New England Journal of Medicine 2005;353:1114–23.PubMedCrossRefGoogle Scholar
  152. 152.
    Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2006;144:865–76.PubMedGoogle Scholar
  153. 153.
    Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut 2006;55:1059–60.PubMedCrossRefGoogle Scholar
  154. 154.
    Keshav S, Ungashe S, Zheng W, Bekker P, Wright K, Schall TJ. CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory & clinical activity in the treatment of Crohn disease. Gastroenterology 2007;132(Suppl 2):A157.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jeanne Tung
    • 1
  • William J. Sandborn
  1. 1.Mayo ClinicSW, RochesterUSA

Personalised recommendations